EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Towards Next-Generation Sequencing as a First-Tier Diagnostic Test for Fructose-1,6-Bisphosphatase Deficiency

Nadine Yazbeck iD, Abir Barhoumi, Pascale E Karam iD

Metabolites · 08.01.2026 · 16 (1) · 56

DOI: 10.3390/metabo16010056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Metabolites, online erschienen am 08.01.2026. Verfasst von Nadine Yazbeck und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center,…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Advances in genomic technologies combined with tandem mass newborn screening have enabled early detection and management of several common inborn errors of metabolism. Fructose-1,6-bisphosphatase deficiency, an autosomal recessive treatable disorder reported in around 150 patients worldwide, remains underdiagnosed despite an excellent prognosis with early detection. Although common in highly consanguineous populations, diagnosis is often delayed due to the non-specific clinical and biochemical profile.

Methods

This report explores the diagnostic pathway using first-tier next-generation sequencing of three novel cases of fructose-1,6-bisphosphatase deficiency in a tertiary care center in Lebanon.

Results

Two patients were diagnosed with first-tier exome sequencing within one month of presentation and had an excellent outcome at 6 years of follow-up. The third patient, undiagnosed for 10 years, suffered from neurological sequalae. The molecular profile was remarkable in two patients for exon 2 deletion in the FBP1 gene, a founder mutation reported in Turkish and Armenian patients, and a rare frameshift mutation in the third case.

Conclusions

The use of next-generation sequencing as as a first-tier test for FBP deficiency is a non-invasive and rapid method for early diagnosis and management of this rare yet treatable disorder. It can detect both disease-causing variants and large deletions, founder mutations as well, delineating the molecular profile in populations where this disorder is highly prevalent.

Schlagwörter

Stichwörter der Autor:innen

FBP1diagnosticsfructose-1,6-bisphosphataseinborn errors of metabolismnext generation sequencing

Autor:innen und Institutionen

  • Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut P.O. Box 2020, Lebanon.
  • Department of Nutrition, American University of Beirut Medical Center, Beirut P.O. Box 2020, Lebanon.
  • Inherited Metabolic Diseases Program, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut P.O. Box 2020, Lebanon.

ORCID-Profile: Nadine Yazbeck, Pascale E Karam

Zitieren

APA

Yazbeck, N., Barhoumi, A., & Karam, P. E. (2026). Towards Next-Generation Sequencing as a First-Tier Diagnostic Test for Fructose-1,6-Bisphosphatase Deficiency. Metabolites, 16(1), 56. https://doi.org/10.3390/metabo16010056

Vancouver

Yazbeck N, Barhoumi A, Karam PE. Towards Next-Generation Sequencing as a First-Tier Diagnostic Test for Fructose-1,6-Bisphosphatase Deficiency. Metabolites. 2026;16(1):56. doi:10.3390/metabo16010056

BibTeX
@article{Yazbeck2026,
  author = {Yazbeck, Nadine and Barhoumi, Abir and Karam, Pascale E},
  title = {Towards Next-Generation Sequencing as a First-Tier Diagnostic Test for Fructose-1,6-Bisphosphatase Deficiency},
  journal = {Metabolites},
  year = {2026},
  volume = {16},
  number = {1},
  pages = {56},
  doi = {10.3390/metabo16010056}
}
Kostenlos starten →